Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - Stifel has reiterated its Buy rating on Alcon Inc. (NYSE:ALC) while maintaining a price target of $100.00. According to InvestingPro data, analysts’ targets range from $86 to $123, with the current stock trading near its 52-week low at $86.98.
The research firm cited Alcon’s market leadership position in the ophthalmology sector as a key factor behind the continued positive outlook.
Stifel views Alcon as a "core holding" in its coverage universe, highlighting the company’s position in what it describes as an "attractive" industry segment.
The firm noted that Alcon currently demonstrates sustainable growth in the mid-single-digit percentage range or higher.
Stifel also pointed to Alcon’s margin expansion potential as another factor supporting its investment thesis for the eye care company.
In other recent news, Alcon has announced its intention to acquire LumiThera, Inc., along with its photobiomodulation device designed for treating early and intermediate dry age-related macular degeneration (AMD (NASDAQ:AMD)). This device, which has received FDA and CE Mark approvals, has shown promising results in improving vision for patients. Additionally, Alcon has received Health Canada approval for its UNITY Vitreoretinal Cataract System, which aims to enhance surgical efficiencies. The company plans to launch this system commercially in early 2026. Furthermore, Alcon’s Clareon PanOptix Pro intraocular lens has also been approved in Canada, featuring advanced technology to reduce light scatter for cataract patients. The lens is expected to be available in early 2026. Stifel has reiterated its Buy rating on Alcon, highlighting potential stabilization in its U.S. intraocular lens business. However, challenges are anticipated in international markets due to increasing competition. These developments reflect Alcon’s ongoing efforts to innovate and expand its product offerings in the eye care sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.